To stop the determination of cerebral most regulated substances

Cerebral will stop prescribing the most controlled substances to new and existing patients, Digital Mental Health Company Confirmed Internal.

According to an email sent to staff on Monday, Cerebral CEO Kyle Robertson said the company would discontinue prescription of controlled substances such as Adral and Xanax for new patients from May 20 and for existing patients from October 15.

“This decision was made by our clinical and regulatory teams, and we will release more details this weekend on how to do it safely and in the best interests of our patients and physicians,” Cerebral said in a statement. Internal.

The company will continue to prescribe drugs to treat opioid use disorders, as those treatment options may be difficult to access, according to InternalReporting. Cerebral her announcement Opioid treatment program in March.

Earlier this month, cerebral Has stopped prescription of controlled substances for new patients and introduced new safety and quality initiatives, such as hiring more assessment capabilities, hiring more psychiatrists and psychiatric nurse practitioners, and setting up a review committee to examine its paid social ads.

Why it matters

The cerebral cortex has undergone increasing scrutiny over the past few months for its prescribed practice. Company Hall The U.S. Department of Justice is investigating possible violations of the Controlled Substances Act. Internal The U.S. Drug Enforcement Administration is also looking at mental health startups.

There is a former cerebral executive, Matthew Trube Has sued the company, alleging that he was fired after expressing concern about unethical prescribing practices and patient safety issues.

A Bloomberg Business Week The investigation since March included interviews with cerebral staff who said they were pressured to prescribe at the expense of their patient care.

Greater trend

As seen by email Internal, Taking steps to stop cerebral prescription because patients can now return to hybrid or personal care. The company started prescriptions at the height of the Kovid-19 epidemic because of DEA suspension rules. Personal evaluation is required for prescription of controlled substances.

The company has defended its prescribed practices in the past. At the annual conference and expo of the American Telemedicine Association Earlier this month, Cerebral Chief Medical Officer Dr. David Mou maintained their quality standards, but acknowledged that mistakes have been made in areas such as marketing and social media campaigns that target young consumers.

Leave a Reply

Your email address will not be published.